(866) 389-4659
Resources Pregnancy Guide Understanding Your Screenings Planning Hospital Bag Checklist Birth Plan Template
Cord Blood 101 Why Stem Cells Matter What Is Cord Blood? What Is Cord Tissue? Public vs. Private Banking Treatment & Research Cellular Materials Clinical Research StemCyte Biologics
Get Started Build Your Plan FAQ Advanced Protection Public Bank Access HLA Matching Newborn Genetic Analysis MaxCell® LifeSaver Guarantee Community Programs Special Programs Refer a Friend Public Banking Expanded Access Program
About Our Impact Who We Are Community Patient Stories
Build Your Plan
Newsroom

Newsroom

Breakthroughs, milestones, and the science shaping the future of cord blood medicine.

Clinical Research

Long COVID Trial Shows 85% Fatigue Resolution with Cord Blood Therapy

"The magnitude of improvement in the treatment arm exceeded our expectations across every fatigue domain."
EClinicalMedicine (The Lancet), January 2026

Phase II results demonstrate significant improvement in post-COVID fatigue using REGENECYTE® cord blood infusion.

January 2026Clinical Research4 min read
Regulatory

FDA Grants Expanded Access for REGENECYTE® in Long COVID

Treatment now available outside of clinical trial settings.

2026
Award

Taiwan BIO Award for Innovation of the Year

Recognized for advancing cord blood therapies and global clinical impact.

2025
Milestone

REGENECYTE® Receives FDA Biologics License

BLA 125764/0 marks full FDA licensure for StemCyte's cord blood product.

2024

All Coverage

View archive →
Research

Toward an HIV Cure: Case Published in Cell

The “New York Patient” achieves HIV-1 remission and possible cure following a CCR5Δ32 haplo-cord transplant.

2023
Regulatory

FDA RMAT Designation for Long COVID

Regenerative Medicine Advanced Therapy designation accelerates the development pathway.

2024
Recognition

Honored at Taiwan Presidential Office

Leadership recognized for contributions to stem cell science and cross-Pacific collaboration.

2025